Abstract
This paper provides the generic pharmaceutical executive with a legal roadmap for acquiring pharmaceutical assets. It describes the three main steps to product acquisition, which are as follows: (1) negotiation and execution of a detailed letter of intent; (2) performance of buyer's due diligence; and (3) negotiation and closing of the acquisition agreement. It also explains the relationship among these three steps and why each step is important to the buyer. In discussing each step of the acquisition process, this paper identifies the key considerations and issues for the buyer to help the buyer mitigate the risks inherent in the acquisition of generic pharmaceutical assets.
Get full access to this article
View all access options for this article.